Nvwm LLC Acquires 14 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nvwm LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 988 shares of the biopharmaceutical company’s stock after buying an additional 14 shares during the period. Nvwm LLC’s holdings in Regeneron Pharmaceuticals were worth $1,039,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Norden Group LLC increased its position in shares of Regeneron Pharmaceuticals by 48.1% in the first quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company’s stock worth $373,000 after purchasing an additional 126 shares during the period. Janney Montgomery Scott LLC increased its holdings in Regeneron Pharmaceuticals by 10.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 26,907 shares of the biopharmaceutical company’s stock valued at $25,898,000 after buying an additional 2,593 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 10.9% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,683 shares of the biopharmaceutical company’s stock valued at $2,582,000 after buying an additional 263 shares in the last quarter. Choreo LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the 1st quarter. Choreo LLC now owns 1,083 shares of the biopharmaceutical company’s stock worth $1,042,000 after acquiring an additional 36 shares during the period. Finally, Fidelis Capital Partners LLC boosted its position in shares of Regeneron Pharmaceuticals by 15.1% during the 1st quarter. Fidelis Capital Partners LLC now owns 419 shares of the biopharmaceutical company’s stock worth $403,000 after acquiring an additional 55 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of Regeneron Pharmaceuticals stock traded up $5.40 during midday trading on Friday, reaching $843.60. The company had a trading volume of 1,087,285 shares, compared to its average volume of 768,492. The stock has a fifty day moving average price of $1,058.43 and a 200 day moving average price of $1,039.88. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The firm has a market cap of $93.00 billion, a PE ratio of 20.88, a P/E/G ratio of 2.88 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.99 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the prior year, the company posted $8.79 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,090.24.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.